GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (FRA:5GH) » Definitions » Notes Receivable

Guardant Health (FRA:5GH) Notes Receivable : €0.0 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Guardant Health Notes Receivable?

Guardant Health's Notes Receivable for the quarter that ended in Mar. 2024 was €0.0 Mil.


Guardant Health Notes Receivable Historical Data

The historical data trend for Guardant Health's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Notes Receivable Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial - - - - -

Guardant Health Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Guardant Health Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Guardant Health Notes Receivable Related Terms

Thank you for viewing the detailed overview of Guardant Health's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardant Health (FRA:5GH) Business Description

Traded in Other Exchanges
Address
3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health (FRA:5GH) Headlines

No Headlines